secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexeo Therapeutics, Inc. (LXEO)
CIK:        0001907108
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-010091
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Lexeo Therapeutics reports positive interim Phase 1/2 clinical data for LX2020 in PKP2-ACM
--------------------------------------------------------------------------------

- LX2020 generally well tolerated in 10 participants; no clinically significant complement activation observed
- Mean PKP2 protein expression increased 93% in low-dose (n=2) and 162% in high-dose cohorts (n=5) by western blot
- Non-sustained ventricular tachycardia reduced 22% (mean) in high-dose cohort (n=5); PVCs improved 14%
- 4 of 5 high-dose participants reported improvement on the PGIC patient-reported outcome scale
- HEROIC-PKP2 enrollment completed Q4 2025; 12-month data for all high-dose participants expected Q4 2026

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1907108/000119312526010091/0001193125-26-010091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1907108/000119312526010091/lxeo-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-010091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer